User: Guest  Login
Title:

Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315).

Document type:
Journal Article
Author(s):
Griesinger, Frank; Sebastian, Martin; Brueckl, Wolfgang M; Hummel, Horst-Dieter; Jaeschke, Bastian; Kern, Jens; Wesseler, Claas; Jänicke, Martina; Fleitz, Annette; Zacharias, Stefan; Hipper, Annette; Groth, Annika; Weichert, Wilko; Dörfel, Steffen; Petersen, Volker; Schröder, Jan; Wilke, Jochen; Eberhardt, Wilfried E E; Thomas, Michael
Abstract:
INTRODUCTION: Patients with metastatic NSCLC (mNSCLC) treated with immune checkpoint inhibitors in clinical practice may often not meet the strict inclusion criteria of clinical trials. Our aim was to assess the trial eligibility of patients with mNSCLC treated with pembrolizumab monotherapy in real-world and to compare the outcome of "trial-ineligible" and "potentially trial-eligible" patients. METHODS: Data from the prospective, clinical research platform CRISP were used to compare patient cha...     »
Journal title abbreviation:
JTO Clin Res Rep
Year:
2024
Journal volume:
5
Journal issue:
4
Fulltext / DOI:
doi:10.1016/j.jtocrr.2023.100626
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/38586301
TUM Institution:
Institut für Allgemeine Pathologie und Pathologische Anatomie (Dr. Mogler komm.)
 BibTeX